Treatment intensification with novel antidiabetic agents alters platelet function parameters in patients with type 2 diabetes
Evanthia Bletsa(National and Kapodistrian University of Athens), Dimitris Tousoulis(National and Kapodistrian University of Athens), Nikolaοs Tentolouris, Zoi Pallantza(Hippocration General Hospital), Maria Kozanitou, Eva Kassi(Laiko General Hospital of Athens), Anastasia Thanopoulou(National and Kapodistrian University of Athens), Gerasimos Siasos(Brigham and Women's Hospital), Andromachi Vryonidou, Konstantinos Mourouzis, Efthimia Pavlou(University of West Attica), Stavroula Α. Paschou(Beth Israel Deaconess Medical Center), Nikolaos Gouliopoulos(National and Kapodistrian University of Athens), Panagiota K. Stampouloglou(National and Kapodistrian University of Athens), Evangelos Oikonomou(National and Kapodistrian University of Athens), Konstantinos Batzias(National and Kapodistrian University of Athens), Marina Zaromytidou, Alexios Antonopoulos, Vasiliki Tsigkou(National and Kapodistrian University of Athens)
Cited by 0
Related Papers
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across Regions
|European Journal of Heart Failure|2016|781
Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis
|Nutrients|2019|475
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
|International Journal of Molecular Sciences|2021|294